Skip to main content
PMC home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2009 Jun 9;10(4):227–233. doi: 10.1007/s10194-009-0133-3

Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification

James A Charles 1,✉, B L Peterlin 2, Alan M Rapoport 3, Steven L Linder 4, Marielle A Kabbouche 5, Fred D Sheftell 6
PMCID: PMC3451739  PMID: 19506799

Abstract

There is evidence that the prevalence of migraine in children and adolescents may be increasing. Current theories of migraine pathophysiology in adults suggest activation of central cortical and brainstem pathways in conjunction with the peripheral trigeminovascular system, which ultimately results in release of neuropeptides, facilitation of central pain pathways, neurogenic inflammation surrounding peripheral vessels, and vasodilatation. Although several risk factors for frequent episodic, chronic, and refractory migraine have been identified, the causes of migraine progression are not known. Migraine pathophysiology has not been fully evaluated in children. In this review, we will first discuss the evidence that early therapeutic interventions in the child or adolescent new onset migraineur, may halt or limit progression and disability. We will then review the evidence suggesting that many adults with chronic or refractory migraine developed their migraine as children or adolescents and may not have been treated adequately with migraine-specific therapy. Finally, we will show that early, appropriate and optimal treatment of migraine during childhood and adolescence may result in disease modification and prevent progression of this disease.

Keywords: Disease modification, Child, Adolescent, Migraine

Full Text

The Full Text of this article is available as a PDF (173.9 KB).

Conflict of interest

None.

References

  • 1.Abu-Arefeh I, Russell G. Prevalence of headache and migraine in school children. Br Med J. 1994;309:765–769. doi: 10.1136/bmj.309.6957.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Split W, Newman W. Epidemiology of migraine among students from randomly selected secondary schools in Lodz. Headache. 1999;39:494–501. doi: 10.1046/j.1526-4610.1999.3907494.x. [DOI] [PubMed] [Google Scholar]
  • 3.Monastero R, Camarda C, Pipia C, Camarda R. Prognosis of migraine headaches in adolescents. Neurology. 2006;67:1353–1356. doi: 10.1212/01.wnl.0000240131.69632.4f. [DOI] [PubMed] [Google Scholar]
  • 4.Linder SL. Do children and adolescents have chronic daily headache? Yes! Curr Pain Headache Rep. 2005;9(5):358–362. doi: 10.1007/s11916-005-0013-8. [DOI] [PubMed] [Google Scholar]
  • 5.Hershey A, et al. Characterization of chronic daily headaches in children in a multidisciplinary headache center. Neurology. 2001;56:1032–1037. doi: 10.1212/wnl.56.8.1032. [DOI] [PubMed] [Google Scholar]
  • 6.Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267(1):64–69. doi: 10.1001/jama.267.1.64. [DOI] [PubMed] [Google Scholar]
  • 7.Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology. 1994;44(6 Suppl 4):S17–S23. [PubMed] [Google Scholar]
  • 8.Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;106:81–89. doi: 10.1046/j.1526-4610.2001.041007629.x. [DOI] [PubMed] [Google Scholar]
  • 9.Kruit MC, Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291:427. doi: 10.1001/jama.291.4.427. [DOI] [PubMed] [Google Scholar]
  • 10.Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81–89. doi: 10.1016/S0304-3959(03)00293-8. [DOI] [PubMed] [Google Scholar]
  • 11.Kabbouche MA, et al. Outcome of a multidisciplinary approach to pediatric migraine at 1, 2, and 5 years. Headache. 2005;45:1298–1303. doi: 10.1111/j.1526-4610.2005.00261.x. [DOI] [PubMed] [Google Scholar]
  • 12.Charles JA, Jotkowitz S. Observations of the “carry-over effect” following successful termination of chronic migraine in the adolescent with short-term dihydroergotamine, dexamethasone and hydroxyzine: a pilot study. J Headache Pain. 2005;6(1):51–54. doi: 10.1007/s10194-005-0148-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hering-Hanit R, Cohen A, Horev Z. Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. J Child Neurol. 2001;16:448–449. doi: 10.1177/088307380101600613. [DOI] [PubMed] [Google Scholar]
  • 14.Raskin NH, Hosobucki Y, Lamb S. Headache may arise from perturbation of brain. Headache. 1987;27:416–420. doi: 10.1111/j.1526-4610.1987.hed2708416.x. [DOI] [PubMed] [Google Scholar]
  • 15.Haas DC, Kent PF, Friedman DI. Headache caused by a single lesion of multiple sclerosis in the periaqueductal grey area. Headache. 1993;33:452–455. doi: 10.1111/j.1526-4610.1993.hed3308452.x. [DOI] [PubMed] [Google Scholar]
  • 16.Lipton R, Pan J. Is migraine a progressive brain disease? JAMA. 2004;291:493–494. doi: 10.1001/jama.291.4.493. [DOI] [PubMed] [Google Scholar]
  • 17.Marcus D. Central sensitization: an important factor in the pathogenesis of chronic headache. Headache Pain. 2003;14(1):19–23. [Google Scholar]
  • 18.D’Amico D, Moschiano F, Bussone G. Early treatment of migraine attacks with triptans: a strategy to enhance outcomes and patient satisfaction? Expert Rev Neurother. 2006;6(7):1087–1097. doi: 10.1586/14737175.6.7.1087. [DOI] [PubMed] [Google Scholar]
  • 19.Silberstein SD. Multimechanistic (sumatriptan–naproxen) early intervention for the acute treatment of migraine. Neurology. 2008;71:114–121. doi: 10.1212/01.wnl.0000316800.22949.20. [DOI] [PubMed] [Google Scholar]
  • 20.Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614–624. doi: 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  • 21.Burstein R, et al. Defeating migraine pain with triptans: the race against the development of cutaneous allodynia. Ann Neurol. 2004;55(1):19–26. doi: 10.1002/ana.10786. [DOI] [PubMed] [Google Scholar]
  • 22.Waeber C, Moskowitz MA. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology. 2003;61:S9–S20. doi: 10.1212/wnl.61.8_suppl_4.s9. [DOI] [PubMed] [Google Scholar]
  • 23.Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology. 2004;63:848–852. doi: 10.1212/01.wnl.0000137107.27585.f7. [DOI] [PubMed] [Google Scholar]
  • 24.Bille B. A 40-year follow-up of school children with migraine. Cephalalgia. 1997;17(4):488–491. doi: 10.1046/j.1468-2982.1997.1704488.x. [DOI] [PubMed] [Google Scholar]
  • 25.Ferrari A, et al. Similarities and differences between chronic migraine and episodic migraine. Headache. 2007;47(1):65–72. doi: 10.1111/j.1526-4610.2006.00629.x. [DOI] [PubMed] [Google Scholar]
  • 26.Wober C, Wober-Bingol C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia. 1991;11(6):251–256. doi: 10.1046/j.1468-2982.1991.1106251.x. [DOI] [PubMed] [Google Scholar]
  • 27.Solomon S, Lipton R, Newman L. Clinical features of chronic daily headache. Headache. 1992;32(7):325–329. doi: 10.1111/j.1526-4610.1992.hed3207325.x. [DOI] [PubMed] [Google Scholar]
  • 28.Mathew NT, et al. Transformed or evolutive migraine. Headache. 1987;27(2):102–106. doi: 10.1111/j.1526-4610.1987.hed2702102.x. [DOI] [PubMed] [Google Scholar]
  • 29.Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 1996;39(4):616–622. doi: 10.1002/art.1780390412. [DOI] [PubMed] [Google Scholar]
  • 30.Fuller G, Bone I. Disease modifying treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;71(Suppl 1):ii20–ii21. doi: 10.1136/jnnp.71.suppl_2.ii20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Fox A. Disease modification in migraine: study design and sample size implications. Headache. 2008;48(8):1169–1175. doi: 10.1111/j.1526-4610.2007.01057.x. [DOI] [PubMed] [Google Scholar]
  • 32.Fanicullace M, DeCesaris F. Preventing chronicity of migraine. J Headache Pain. 2005;6(4):331–333. doi: 10.1007/s10194-005-0224-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Petrella R, Speechley M, Kleinstiver P, Ruddy T. Impact of a social marketing media campaign on public awareness of hypertension. Am J Hypertens. 2005;18(2):270–275. doi: 10.1016/j.amjhyper.2004.09.012. [DOI] [PubMed] [Google Scholar]
  • 34.Loder D, Biondi D. Disease modification in migraine: a concept that has come of age? Headache. 2007;43(2):135–143. doi: 10.1046/j.1526-4610.2003.03033.x. [DOI] [PubMed] [Google Scholar]
  • 35.Bigal ME, Lipton RB. Modifiable risk factors for migraine progression (or for chronic daily headaches)—clinical lessons. Headache. 2006;46(Suppl 3):S144–S146. doi: 10.1111/j.1526-4610.2006.00566.x. [DOI] [PubMed] [Google Scholar]
  • 36.Boardman HF, Thomas E, Millson DS, Croft PR. The natural history of headache: predictors of onset and recovery. Cephalalgia. 2006;9:1080–1088. doi: 10.1111/j.1468-2982.2006.01166.x. [DOI] [PubMed] [Google Scholar]
  • 37.Hershey A, et al. Obesity in the pediatric headache population: a multicenter study. Headache. 2009;49:170–177. doi: 10.1111/j.1526-4610.2008.01232.x. [DOI] [PubMed] [Google Scholar]
  • 38.Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. Headache. 2008;48(1):16–25. doi: 10.1111/j.1526-4610.2007.00970.x. [DOI] [PubMed] [Google Scholar]
  • 39.Peterlin L, Calhoun A, Siegel S, Mathew N. Rational combination therapy in refractory migraine. Headache. 2008;48(6):805–819. doi: 10.1111/j.1526-4610.2008.01142.x. [DOI] [PubMed] [Google Scholar]
  • 40.Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002;22:491–512. doi: 10.1046/j.1468-2982.2002.00386.x. [DOI] [PubMed] [Google Scholar]
  • 41.Brandes JL, Kudrow D, Stark SR, O’Carroll P, Adelman JU, O’Donnell FJ, Alexander AJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan–naproxen for acute treatment of migraine—a randomized trial. JAMA. 2007;297:1443–1454. doi: 10.1001/jama.297.13.1443. [DOI] [PubMed] [Google Scholar]
  • 42.Ahoen K, et al. A randomized trial of rizatriptan in migraine attacks in children. Neurology. 2006;67:1135–1140. doi: 10.1212/01.wnl.0000238179.79888.44. [DOI] [PubMed] [Google Scholar]
  • 43.Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache. 1994;34(10):578–584. doi: 10.1111/j.1526-4610.1994.hed3410578.x. [DOI] [PubMed] [Google Scholar]
  • 44.Winner P, et al. A randomized, double blind, placebo controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106(5):989–997. doi: 10.1542/peds.106.5.989. [DOI] [PubMed] [Google Scholar]
  • 45.Linder SL, Dowson A. Zolmatriptan provides effective migraine relief in adolescents. Int J Clin Pract. 2000;54:466–469. [PubMed] [Google Scholar]
  • 46.Charles JA. Almotriptan in the acute treatment of migraine in patients 11–17 years old—a study of efficacy and safety. J Headache Pain. 2006;7:95–97. doi: 10.1007/s10194-006-0288-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Pageler L, Katsarava Z, Limmroth V et al (2004) Prednisone in the treatment of medication withdrawal headache following medication overuse headache: a placebo-controlled, double-blind, and randomized pilot study. Cephalalgia 24:792

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES